EFMC-ISMC 2014

XXIII International Symposium on Medicinal Chemistry

 Lisbon, Portugal    September 7-11, 2014

Programme Schedule


16:15

Opening Ceremony

16:35

Portugal: the Right Place to build Partnerships in Health

Dr Joaquim CUNHA
HEALTH CLUSTER PORTUGAL, Maia, Portugal

16:50

Partnership between Public and Private Sources: Pharma and IMI Perspective

Dr Paul Peter TAK
EFPIA, Brentford, United Kingdom

17:10

EFMC Award Ceremony

17:35

The Nauta Award for Pharmacochemistry
Pursuing Compound Quality

Dr Paul LEESON
GLAXOSMITHKLINE, Nuneaton, United Kingdom

18:20

High Resolution Mass Spectrometry in Clinical Proteomics

Prof. Dr Matthias MANN
MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany

19:10

Welcome Reception

08:30

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Small Molecule Control Of Intracellular Protein Levels

Prof. Craig CREWS
UNIVERSITY OF YALE, New Haven, United States

09:15

The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery
Thermodynamics Assisted Drug Discovery

Dr György G. FERENCZY
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary


Prof. Gyorgy KESERU
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary

10:00

Exhibition & Coffee

10:30

Start of sessions

1.1 Inflammation: the Common Link in Multifactorial Disorders?
1.2 Computational Approaches To Guide Medicinal Chemistry
1.3 Organic Synthesis that Changed Medicinal Chemistry
1.1 Inflammation: the Common Link in Multifactorial Disorders?
11:55
Discovery of Small Molecule Rorγ Modulators for the Treatment of Autoimmune Diseases
Dr Frank NARJES
ASTRAZENECA, Mölndal, Sweden
1.2 Computational Approaches To Guide Medicinal Chemistry
11:55
P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies
Mr Ricardo FERREIRA
FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal
1.3 Organic Synthesis that Changed Medicinal Chemistry
11:55
Development of Novel Building Blocks to Accelerate Drug Discovery
Dr Pavel MYKHAILIUK
ENAMINE, Kyiv, Ukraine
12:15

Exhibition & Lunch

13:15

Start of sessions

2.4 Combating Antibiotic Resistance
2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis
2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury
(Eufeps Session)
2.4 Combating Antibiotic Resistance
13:20
Aminoglycoside Mechanisms of Action, Resistance and Toxicity – Prospects for Antibiotic Drug Development
Prof. Erik BOËTTGER
UNIVERSITY OF ZÜRICH, Zürich, Switzerland
2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis
14:40
From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein
Dr Fanny ROUSSI
ICSN - CNRS, Gif sur Yvette, France
2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury
(Eufeps Session)
14:40
Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?
Dr Alexandra ANTUNES
INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal
15:00

Exhibition & Coffee

15:30

MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application

Prof. Christian HEINIS
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland

15:55

Start of sessions

17:30

Poster Session I and Networking

19:30

End of the day

20:30

Concert (free of charge, but subject to registration)

08:30

Prize Ceremony

08:35

EFMC Prize for a Young Medicinal Chemist in Industry
Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC

Dr Grazia PIIZZI
NOVARTIS PHARMA, Basel, Switzerland

08:55

EFMC Prize for a Young Medicinal Chemist in Academia
Inhibitors and Substrates of the Human Lysine Deacylase Enzymes

Prof. Christian A. OLSEN
UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark

09:15

Plenary Lecture

Dr Sabine HADIDA
VERTEX PHARMACEUTICALS, San Diego, United States

10:00

Exhibition & Coffee

10:30

Start of sessions

4.8 Applications of Positron Emission Tomography in Drug Discovery
(ACS Session I)
4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers
4.10 Organic Synthesis: New Developments
(EuCHemS Session)
4.8 Applications of Positron Emission Tomography in Drug Discovery
(ACS Session I)
11:35
Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging
Dr Sam BONACORSI
BRISTOL-MYERS SQUIBB, Princeton, United States
4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers
11:55
Interrogation the Bromodomain Family through Chemical Biology
Dr Steve BELLON
CONSTELLATION PHARMACEUTICALS, Cambridge, United States
4.10 Organic Synthesis: New Developments
(EuCHemS Session)
11:55
Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases
Prof. Marko D. MIHOVILOVIC
VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria
12:15

Exhibition & Lunch

13:15

Start of sessions

5.11 Oncology: Kinases and Beyond
5.12 Recent Advances in Anti-infective Agents
(AFMC Session)
5.13 New Strategies for Lead Generation
5.11 Oncology: Kinases and Beyond
14:40
Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a
Dr Michael MICHAELIDES
ABBVIE, North Chicago, United States
5.12 Recent Advances in Anti-infective Agents
(AFMC Session)
14:40
Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists
Prof. Marko ANDERLUH
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
5.13 New Strategies for Lead Generation
14:00
The Impact of Polypharmacology on Lead Generation
Dr Jordi MESTRES
IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain
15:00

Exhibition & Coffee

15:30

Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery

Prof. Chas BOUNTRA
UNIVERSITY OF OXFORD, Oxford, United Kingdom

16:30

Poster Session II and Networking

18:30

End of the day

08:30

IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D

Dr Helmut BUSCHMANN
PHARMA CONSULTING AACHEN, Aachen, Germany

09:15

Innovation Through Chemistry at the Interfaces of the Scientific Disciplines

Dr Martin MISSBACH
NOVARTIS, Basel, Switzerland

10:00

Exhibition & Coffee

10:30

Start of sessions

6.14 New Chemical Entities: Beyond Small Molecules
6.15 Novel Agents for the Treatment of C. Difficile
(ACS Session II)
6.16 Kinetic and Thermodynamic Aspects of Ligand Binding
6.14 New Chemical Entities: Beyond Small Molecules
11:35
Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells
Dr Jörg VOLLMER
NEXIGEN, Cologne, Germany
6.15 Novel Agents for the Treatment of C. Difficile
(ACS Session II)
11:55
Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Dr Philippe PANCHAUD
ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland
6.16 Kinetic and Thermodynamic Aspects of Ligand Binding
11:55
CRTH2: Can Residence Time Help?
Dr Elena GOMEZ
ALMIRALL, BARCELONA, Spain
12:15

Exhibition & Lunch

13:15

Start of sessions

7.17 Recent Highlights in Medicinal Chemistry
7.18 Hot Topics in Ion Channels
7.19 Allosteric Modulators for CNS Diseases
7.17 Recent Highlights in Medicinal Chemistry
14:40
Novel Potent Inhibitors of the Histone Demethylase KDM1A
Dr Paola VIANELLO
EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy
7.18 Hot Topics in Ion Channels
14:40
Discovery of Ivacaftor (Vx-770), a Cftr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients
Dr Sabine HADIDA
VERTEX PHARMACEUTICALS, San Diego, United States
7.19 Allosteric Modulators for CNS Diseases
14:40
Antibodies as Tools to Enable Small Molecule Drug Discovery
Dr Marta WESTWOOD
UCB, Slough, United Kingdom
15:00

Excursions

20:00

Banquet

08:30

Start of sessions

8.20 GPCR Structural Biology: New Therapeutic Opportunities?
8.21 Neglected Tropical Diseases: Shaping Future Trends
8.22 New Therapies for Metabolic Disorders
8.20 GPCR Structural Biology: New Therapeutic Opportunities?
09:55
Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening
Dr David RODRIGUEZ DIAZ
STOCKHOLM UNIVERSITY, Solna, Sweden
8.21 Neglected Tropical Diseases: Shaping Future Trends
09:55
Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei
Prof. Jennifer WOODRING
NORTHEASTERN UNIVERSITY, Boston, United States
8.22 New Therapies for Metabolic Disorders
09:15
1,1’-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Dr Thomas TRIESELMANN
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany
10:15

Exhibition & Coffee & Snacks

10:45

Start of sessions

9.23 Late Breaking News
9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options
9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling
9.23 Late Breaking News
12:10
Identifying Selective Inhibitors of FGFR4 Kinase
Dr Kurt PIKE
ASTRAZENECA, Cambridge, United Kingdom
9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options
12:10
The Evolution of an in vivo Efficacious Bace1 Inhibitor
Dr Daniel OEHLRICH
JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium
9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling
11:50
A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement
Mr Alban BUJARD
UNIVERSITY OF GENEVA, Geneva, Switzerland
12:30

Closing Lecture
Personalised Medicinal Systems Chemistry

Prof. Hans WESTERHOFF
VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands

13:15

Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2016